UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 190

Sortiert nach

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Neurology, 2020-08, Vol.95 (8), p.e943

2020

Link zum Volltext

Verfügbarkeit prüfen

Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study

Neurology, 2021-08, Vol.97 (8), p.e803

2021

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers and clinical trials in ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.120979, Article 120979

Genge, Angela

2023

Link zum Volltext

Verfügbarkeit prüfen

The future of ALS diagnosis and staging: where do we go from here?

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2023-04, Vol.24 (3-4), p.165-174

2023

Link zum Volltext

Verfügbarkeit prüfen

MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design

Neurodegenerative disease management, 2021-12, Vol.11 (6), p.431-443

2021

Link zum Volltext

Verfügbarkeit prüfen

HERV-K inactive or potential pathogens from within?

Journal of the neurological sciences, 2021-04, Vol.423, p.117359-117359, Article 117359

2021

Link zum Volltext

Verfügbarkeit prüfen

Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2024-05, Vol.25 (3-4), p.225-236

2024

Link zum Volltext

Verfügbarkeit prüfen

Edaravone administration in pivotal clinical Study 19

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2019-04, Vol.20 (3-4), p.298-299

2019

Link zum Volltext

Verfügbarkeit prüfen

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

PM & R, 2015-07, Vol.7 (7), p.677-684

2015

Link zum Volltext

Verfügbarkeit prüfen

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Journal of the neurological sciences, 2023-12, Vol.455, p.121088, Article 121088

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Journal of the neurological sciences, 2023-12, Vol.455, p.121718, Article 121718

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.122737, Article 122737

2023

Link zum Volltext

Verfügbarkeit prüfen

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Journal of the neurological sciences, 2023-12, Vol.455, p.122738, Article 122738

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

JAMA neurology, 2020-05, Vol.77 (5), p.582

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Neurology, 2021-02, Vol.96 (6), p.e853

2021

Link zum Volltext

Verfügbarkeit prüfen

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS

Muscle & nerve, 2020-08, Vol.62 (2), p.156-166

2020

Link zum Volltext

Verfügbarkeit prüfen

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2020-01, Vol.21 (1-2), p.5-14

2020

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic delay in amyotrophic lateral sclerosis

European journal of neurology, 2023-09, Vol.30 (9), p.2595-2601

2023

Link zum Volltext

Verfügbarkeit prüfen

Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment

Muscle & nerve, 2021-11, Vol.64 (5), p.532-537

2021

Link zum Volltext

Verfügbarkeit prüfen

Speech timing and monosyllabic diadochokinesis measures in the assessment of amyotrophic lateral sclerosis in Canadian French

International journal of speech language pathology, 2024-04, Vol.ahead-of-print (ahead-of-print), p.1-11

2024

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

Journal of the neurological sciences, 2023-12, Vol.455, p.122025, Article 122025

2023

Link zum Volltext

Verfügbarkeit prüfen

A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD)

Dysphagia, 2018-12, Vol.33 (6), p.789-802

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 190

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

PublikationsformBücher

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(153)

Publikationsform

Buchkapitel
(113)
Artikel
(77)

Sprache

Englisch
(190)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(60)
Science & Technology
(60)
Neurosciences & Neurology
(54)
Clinical Neurology
(50)
Humans
(50)
Amyotrophic Lateral Sclerosis
(29)
Female
(25)
Middle Aged
(25)
Male
(24)
Adult
(19)
Aged
(18)
Amyotrophic Lateral Sclerosis - Drug Therapy
(18)
Neurosciences
(16)
Arts & Humanities
(14)
Double-Blind Method
(14)
Neurology
(14)
Disease Progression
(13)
Clinical Trials
(12)
Treatment Outcome
(12)
Amyotrophic Lateral Sclerosis - Diagnosis
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study

Biomarkers and clinical trials in ALS

Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy

The future of ALS diagnosis and staging: where do we go from here?

MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design

HERV-K inactive or potential pathogens from within?

Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment

Edaravone administration in pivotal clinical Study 19

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Diagnostic delay in amyotrophic lateral sclerosis

Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment

Speech timing and monosyllabic diadochokinesis measures in the assessment of amyotrophic lateral sclerosis in Canadian French

Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD)

Aktive Filter

Suchergebnisse filtern